|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Metabolism||Hepatic and via erythrocytes|
|Half-life||0.4-0.8 hours (1-1.6 hours for active metabolite)|
|Excretion||Urine (95%), faeces (<4%)|
|Mol. mass||278.31 g/mol|
Pentoxifylline (INN, BAN, USAN) or oxpentifylline (AAN) is a drug commonly sold by Sanofi under the brand name Trental. Its chemical name is 1-(5-oxohexyl)-3, 7-dimethylxanthine. Pentoxifylline is a xanthine derivative. Other brand names include Pentox, Pentoxil and Flexital.
Other indications for which the literature supports its use in include:
- Pentoxyphylline is also used to prevent renal toxicity in cases of alcoholic hepatitis. 
Uncommon (0.1-1% frequency):
Rare (<0.1% frequency):
- Intolerance to pentoxifylline or other xanthine derivatives
- Recent retinal or cerebral haemorrhage
- Risk factors for haemorrhage
This drug is passed into the breast milk. Animal studies have shown no evidence of teratogenicity at high doses.
Like other methylated xanthine derivatives, pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene  synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. Pentoxifylline is also an antagonist at adenosine 2 receptors.
- Lisofylline, an active metabolite of pentoxifylline
- "Trental, Pentoxil (pentoxifylline) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 3 February 2014.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust.
- "PRODUCT INFORMATION TRENTAL® 400" (PDF). TGA eBusiness Services. sanofi-aventis australia pty limited. 25 March 2010. Retrieved 3 February 2014.
- Salhiyyah, Kareem; Senanayake, Eshan; Abdel-Hadi, Mohammed; Booth, Andrew; Michaels, Jonathan A (Jan 18, 2012). Salhiyyah, Kareem, ed. "Pentoxifylline for intermittent claudication". Cochrane Database Syst Rev 1 (1): CD005262.
- "PENTOXIFYLLINE tablet, extended release [Apotex Corp.]". DailyMed. Apotex Corp. February 2013. Retrieved 3 February 2014.
- "Trental 400 - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Sanofi. 10 October 2013. Retrieved 3 February 2014.
- "European Pentoxifylline Multi-Infarct Dementia Study". European neurology 36 (5): 315–21. 1996.
- Brant, WO; Dean, RC; Lue, TF (February 2006). "Treatment of Peyronie's disease with oral pentoxifylline". Nature Clinical Practice Urology 3 (2): 111–115.
- Beegle, SH; Barba, K; Gobunsuy, R; Judson, MA (2013). "Current and emerging pharmacological treatments for sarcoidosis: a review." (PDF). Drug Design, Development and Therapy 7: 325–38.
- Laczy, B; Cseh, J; Mohás, M; Markó, L; Tamaskó, M; Koszegi, T; Molnár, GA; Wagner, Z; Wagner, L; Wittmann, I (Jun 2009). "Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus.". Acta diabetologica 46 (2): 105–11.
- Sherer, JT; Glover, PH (Sep 2000). "Pentoxifylline for sickle-cell disease.". The Annals of pharmacotherapy 34 (9): 1070–4.
- Akriviadis, E; Botla, R; Briggs, W; Han, S; Reynolds, T; Shakil, O (December 2000). "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial". Gastroenterology 119 (6): 1637–1648.
- Li, W; Zheng, L; Sheng, C; Cheng, X; Qing, L; Qu, S (April 2011). "Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease.". Lipids in health and disease 10: 49.
- Alborzi, S; Ghotbi, S; Parsanezhad, ME; Dehbashi, S; Alborzi, S; Alborzi, M (Jan–Feb 2007). "Pentoxifylline therapy after laparoscopic surgery for different stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study.". Journal of minimally invasive gynecology 14 (1): 54–8.
- Okunieff, P; Augustine, E; Hicks, JE; Cornelison, TL; Altemus, RM; Naydich, BG; Ding, I; Huser, AK; Abraham, EH; Smith, JJ; Coleman, N; Gerber, LH (Jun 1, 2004). "Pentoxifylline in the treatment of radiation-induced fibrosis.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22 (11): 2207–13.
- Delanian, S; Porcher, R; Rudant, J; Lefaix, JL (2005). "Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis,". J Clin Oncol 23 (34): 8570–8579.
- Pereda, J; Gómez-Cambronero, L; Alberola, A; Fabregat, G; Cerdá, M; Escobar, J; Sabater, L; García-De-La-Asunción, J; Viña, J; Sastre, J (2006). "Co-administration of pentoxifylline and thiopental causes death by acute pulmonary oedema in rats". British Journal of Pharmacology 149 (4): 450–5.
- Essayan DM. (2001). "Cyclic nucleotide phosphodiesterases". J Allergy Clin Immunol. 108 (5): 671–80.
- Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. (2008). "Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition". Clinics (Sao Paulo). 63 (3): 321–8.
- Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (February 1999). "Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages". Am. J. Respir. Crit. Care Med. 159 (2): 508–11.
- Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. (2005). "Leukotrienes: underappreciated mediators of innate immune responses". J Immunol. 174 (2): 589–94.
- Ward, A; Clissold, SP (1987). "Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy". Drugs 34 (1): 50–97.
- Rodríguez-Morán M, Guerrero-Romero F (February 2008). "Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes". Curr Diabetes Rev 4 (1): 55–62.
- Trental information from Aventis
- Reprinted article on veterinary use subscription required